anbenitamab + docetaxel + carboplatin

anbenitamab + docetaxel + carboplatin is an investigational combination regimen consisting of anbenitamab (KN026), a bispecific monoclonal antibody targeting two distinct domains of the human epidermal growth factor receptor 2 (HER2); docetaxel (often administered as the solvent-free, albumin-bound formulation HB1801), a microtubule inhibitor; and carboplatin, a platinum-based DNA alkylating agent. Anbenitamab simultaneously binds to extracellular domains II and IV of HER2, effectively combining the mechanisms of pertuzumab and trastuzumab to block HER2 signaling, promote receptor internalization, and induce antibody-dependent cellular cytotoxicity (ADCC). Docetaxel inhibits microtubule depolymerization, arresting the cell cycle, while carboplatin induces DNA cross-linking to trigger apoptosis. This combination is primarily developed by Alphamab Oncology and CSPC Pharmaceutical Group (via its subsidiary JMT-Bio) for the neoadjuvant treatment of HER2-positive early or locally advanced breast cancer, demonstrating significant improvements in total pathological complete response (tpCR) in the Phase III Neo-Healer trial.